By Rebecca Adler, PharmD, BCPS, Clinical Pharmacist. Medically reviewed by Dr. Hassan Karimi, MD, Board-Certified Endocrinology.
Lisa, 37, lives in Raleigh, North Carolina, and teaches fourth grade. When she started compounded tirzepatide at 2.5 mg weekly last September, she weighed 247 pounds at five-foot-six. "I didn't expect much the first month," she told her prescriber at the four-week follow-up. "I lost nine pounds, but the bigger thing was I stopped thinking about the vending machine at 2 p.m." By week sixteen, after titrating to 10 mg, she was down 38 pounds. She's not a clinical trial participant. She's one person. But her experience tracks closely enough with the published data that it's worth using as a jumping-off point to talk about what "zepbound before and after" actually means, and where the limits of that phrase are.
This article is part of the FormBlends ultimate guide to compounded tirzepatide and the GLP-1 Long-Term & Maintenance hub.
Key takeaways
- Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist.
- Head-to-head: SURPASS-2 showed greater weight and A1c reduction with tirzepatide versus semaglutide 1 mg in type 2 diabetes.
- Indirect comparisons for obesity indications also tend to favor tirzepatide, with significant individual variance.
- Compounded tirzepatide is not FDA-approved. The FDA does not pre-review compounded medications.
What People Actually Mean When They Search This
The phrase "zepbound before and after" gets about 4,400 U.S. searches a month. Most of those people aren't looking for a pharmacology lecture. They want to see real results, compare them against what the trials promise, and figure out whether this medication is worth the cost, the weekly injections, and the nausea stories they've read about.
Fair enough. But the honest answer requires pulling from two places: head-to-head trial data (which is limited) and indirect evidence across separate studies. Neither gives you a clean, guaranteed number. Here's the thing, though: together they paint a picture that's more useful than any single before-and-after photo on Instagram.
A quick orientation. Liraglutide (Saxenda) is a daily injection, FDA-approved for weight management since 2014, with the longest post-marketing safety record in the class. Semaglutide and tirzepatide are both weekly injections. The comparison that matters most for people searching "zepbound before and after" is tirzepatide versus semaglutide, because those two dominate the conversation right now.
A Composite Patient, Walking Through Month One
Consider someone like Lisa: late 30s, BMI in the obesity range, no diabetes, no history of pancreatitis or gallbladder disease. Starting dose: 2.5 mg weekly. The pharmacy ships 10 mg/mL vials. The patient draws up with a U-100 0.3 mL syringe.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The first month is boring on purpose. Pick an injection day. Learn the technique. Drink more water than you think you need. Adjust meals to account for early satiety (because the first time you eat a normal-sized dinner and feel like you swallowed a bowling ball, you'll understand why). No dose escalation yet.
At week four, a follow-up visit. If side effects have been mild (some queasiness, maybe mild constipation), the plan is typically to escalate to 5 mg weekly.
The figures and protocols cited here trace back to peer-reviewed publications and FDA prescribing information for brand-name products. Compounded formulations are not FDA-reviewed, and any practical guidance about compounded products reflects the standard clinical protocol for the underlying active ingredient.
What the Published Trials Tell Us
Three studies matter most for context:
SELECT (Lincoff et al., NEJM 2023) studied cardiovascular outcomes of semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity.
STEP 1 (Wilding et al., NEJM 2021) evaluated semaglutide 2.4 mg weekly in adults with obesity over 68 weeks.
SURMOUNT-3 (Wadden et al., Nat Med 2023) evaluated tirzepatide following a 12-week intensive lifestyle intervention lead-in.
In SURPASS-2, tirzepatide at its higher doses produced greater weight reduction and A1c improvement than semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. That's the closest thing to a direct comparison we have.
But trial averages are like the average depth of a swimming pool. Useful, maybe, but not if you're standing at the deep end. SURMOUNT-1 reported substantial differences in response within the same dose arm. Some participants lost considerably more than the mean; others, considerably less. That's the normal pattern across every GLP-1 trial ever run.
Related reading in this cluster
How Clinicians Actually Make the Decision
The four factors prescribers weigh when choosing between agents:
- Efficacy data for the patient's specific indication. Obesity alone versus obesity plus type 2 diabetes changes the calculus.
- Side-effect profile in context. Someone with a history of reflux, for instance, may need slower titration and earlier dietary adjustments (more on that below).
- Cost and access realities. This is not theoretical. Brand-name tirzepatide and semaglutide cost over $1,000/month without insurance coverage. Compounded versions are significantly cheaper but come with a different set of considerations around quality and regulatory oversight.
- Patient preference. Some patients have a strong preference about injection frequency, needle size, or the fact that they've seen a friend do well on one agent.
No single factor dominates for every patient. And I'll say something slightly opinionated here: the decision about which GLP-1 agent to start is less important than staying on therapy long enough for the medication to work. People agonize over tirzepatide versus semaglutide like they're choosing a college. The more consequential choice is whether they show up for the follow-up visits.
Follow-up Is Where the Real Results Live
This is the unsexy part. The part that doesn't make it into before-and-after posts.
Routine touchpoints typically happen every four weeks during the first three months, then every two to three months once a stable dose is reached. Each visit covers tolerability, adherence, lifestyle inputs (nutrition, resistance training, sleep), and whether the plan needs adjustment.
These visits aren't a formality. They're the venue for course correction: adjusting a dose that's causing too much nausea, catching a patient who stopped exercising, or spotting early signs that the medication effect is plateauing and the protocol needs a change.
The strongest predictor of long-term outcome across the entire GLP-1 class? Months on therapy at or near the maintenance dose. That single variable matters more than which agent you're on, which dose you reach, or how much weight you lost in the first eight weeks.
Related reading from adjacent topics
When the Scenario Gets Complicated
Real patients don't arrive in neat clinical-trial packaging. Three common variations:
The reflux patient. Same scenario, but with a history of intermittent GERD. The plan shifts: meal composition and timing get adjusted earlier, and the threshold to pause or slow dose escalation drops. Tolerability becomes the primary constraint, not the titration schedule on paper.
The type 2 diabetes patient. Same scenario, but now on metformin. A1c monitoring gets coordinated into the follow-up cadence, and the prescriber watches for any hypoglycemia signal, especially if other glucose-lowering medications are in the mix.
The cost-constrained patient. Same scenario, but insurance denies coverage at month three. The plan adapts: reassess dosing strategy, frequency, whether a holding dose can preserve clinical benefit at a lower monthly cost. This happens more often than people realize.
The Most Underrated Habit
A simple weekly log. Weight, injection date, side effects (rated 1 to 5), any notable dietary or exercise changes.
It compresses six months of context into a single page. It makes every follow-up visit dramatically more productive. And it gives you an honest record of your own before-and-after that's more useful than any number you'll find on Reddit, because it's yours.
Tolerability drives adherence. Adherence drives outcomes. A patient who tolerates the medication well at month six is far more likely to still be on therapy at month eighteen, where the larger absolute results live.
Frequently Asked Questions
Is this something I should discuss with a clinician?
Yes. Any question that affects how a prescription medication is dosed, stored, or administered is worth raising with your prescriber. This article is general education, not a substitute for individualized clinical guidance.
Which option produces more weight loss on average?
In SURPASS-2, tirzepatide produced greater weight reduction than semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. Indirect comparisons for the obesity indications also tend to favor tirzepatide, but trial-by-trial variance is real and individual response varies.
Is one option safer than the other?
Both share the GLP-1 side-effect profile and class warnings. Differences in tolerability across agents exist but are typically modest at the patient level. The prescriber will weigh comorbidities and contraindications to choose the right starting agent.
Can I switch from one to the other?
Yes, switching is a routine clinical decision. The new agent is typically started at its lowest dose and re-titrated rather than jumping to a "dose-equivalent" on day one.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Compounded medications are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a personalized formulation is clinically appropriate.
How long does it take to see results?
Most patients notice appetite changes within the first two weeks. Measurable weight loss typically appears by week four, though the magnitude varies widely. The published trials measured primary endpoints at 68 to 72 weeks, which gives you a sense of how long the full effect takes to develop.
What if I can't tolerate the side effects?
Common GI side effects (nausea, constipation, occasional diarrhea) often improve with slower titration, dietary adjustments, and adequate hydration. If they don't, your prescriber may hold the current dose longer before escalating, reduce the dose temporarily, or discuss switching agents. Severe or persistent symptoms always warrant a clinical conversation.
Continue the series
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About this article
Written by Rebecca Adler, PharmD, BCPS (Clinical Pharmacist). Medically reviewed by Dr. Hassan Karimi, MD (Board-Certified Endocrinology). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.